Argatroban synthetic thrombin inhibitor regulatory update

TXB and partner SB filed an sNDA with the FDA to expand the label for Argatroban to include patients who have or are at risk of developing heparin-induced thrombocytopenia (HIT) and who are undergoing percutaneous coronary intervention, including angioplasty. The drug is approved to prevent or treat thrombosis associated with HIT. ...